Cristi R. King

CYP4F2 genetic variant alters required warfarin dose

Michael D. Caldwell, Tarif Awad, Julie A. Johnson et al. · Blood · 2008 · 522 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer

Sharon Marsh, Cristi R. King, Gillian Gifford et al. · Journal of Clinical Oncology · 2007 · 237 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty

Brian F. Gage, Anne R. Bass, Hannah Lin et al. · JAMA · 2017 · 236 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741

Howard L. McLeod, Daniel J. Sargent, Sharon Marsh et al. · Journal of Clinical Oncology · 2010 · 216 citations · Full text

Medicine, Oncology, Pharmacology +17

ABCG2 Pharmacogenetics

Floris A. de Jong, Sharon Marsh, Ron H.J. Mathijssen et al. · Clinical Cancer Research · 2004 · 206 citations

Medicine, Genetics, Pharmacology +17